Filamin A in triple negative breast cancer

被引:1
|
作者
Giovannelli, Pia [1 ]
Di Donato, Marzia [1 ]
Licitra, Fabrizio [1 ]
Sabbatino, Emilia [1 ]
Tutino, Viviana [1 ]
Castoria, Gabriella [1 ]
Migliaccio, Antimo [1 ]
机构
[1] Univ Campania L Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy
关键词
Triple negative breast cancer; Filamin A; TNBC marker; Androgen receptor; ACTIN-BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; ANDROGEN RECEPTOR; CROSS-LINKING; EXPRESSION; INVASION; SURVIVAL; FLNA; PHOSPHORYLATION; MIGRATION;
D O I
10.1016/j.steroids.2024.109380
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in "collaboration" with other proteins with a relevant role in this BC subgroup.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [42] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [43] Trials of Immunotherapy in Triple Negative Breast Cancer
    Ozge Gumusay
    Chiara A. Wabl
    Hope S. Rugo
    Current Breast Cancer Reports, 2021, 13 : 171 - 185
  • [44] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [45] Advanced Triple Negative Breast Cancer in Pregnancy
    Chong, Tze Huat
    Durairaj, Gunaseelan G.
    Hayati, Firdaus
    Azizan, Nornazirah
    Ahmedy, Fatimah
    Rashid, Nor Faezan Abdul
    GAZI MEDICAL JOURNAL, 2020, 31 (04): : 663 - 665
  • [46] Triple negative breast cancer in the era of miRNA
    Sabit, Hussein
    Cevik, Emre
    Tombuloglu, Huseyin
    Abdel-Ghany, Shaimaa
    Tombuloglu, Guzin
    Esteller, Manel
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [47] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [48] Is triple negative a prognostic factor in breast cancer?
    Nishimura, R.
    Arima, N.
    Osako, T.
    Okumura, Y.
    EJC SUPPLEMENTS, 2008, 6 (07): : 87 - 87
  • [49] Chemoimmunotherapy for Triple-Negative Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (24): : 2521 - 2521
  • [50] Nanomaterial Technology and Triple Negative Breast Cancer
    Hou, Kai
    Ning, Zeng
    Chen, Hongbo
    Wu, Yiping
    FRONTIERS IN ONCOLOGY, 2022, 11